NASDAQ · SYRE
Spyre Therapeutics, Inc.
$96.11-$2.86 (-2.88%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.85% below the high.
Loading market information…
NASDAQ · KRON · USD
Stock price, earnings
Quote as of Jun 20, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Kronos Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.73% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kronos Bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kronos Bio, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to the identification and advancement of innovative therapies for cancer. Its therapeutic strategy centers on modulating dysregulated transcription factors and the intricate transcriptional regulatory networks that fuel oncogenic activity. The company's primary investigational drug, entospletinib (ENTO), is an orally administered, selective inhibitor of spleen tyrosine kinase (SYK), designed for patients with acute myeloid leukemia. A registrational Phase 3 clinical trial is slated to evaluate ENTO in combination with induction chemotherapy for acute myeloid leukemia patients who possess NPM1 mutations. Furthermore, Kronos Bio is progressing KB-0742, an orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor, which is currently undergoing Phase 1/2 clinical assessment for the treatment of MYC-amplified solid tumors. Established in 2017, the company maintains its headquarters in San Mateo, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2023 | Nov 13, 2023 | -$0.54-5.88% vs estimate | $917.00K-39.67% vs estimate |
|---|
| Q2 2023 | Aug 8, 2023 | -$0.52-4.0% vs estimate | $1.86M+11.62% vs estimate |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$96.11-$2.86 (-2.88%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.85% below the high.
$18.20+$16.47 (+952.02%)
Reneo Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.05% below the high.
$1.48+$0.01 (+0.68%)
Achilles Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 1.99% below the high.
$0.68-$0.04 (-5.84%)
Rein Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.61% below the high.
$1.48$0.00 (0.0%)
TCR2 Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.86% below the high.
$22.47-$0.59 (-2.56%)
Sigilon Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.75% below the high.
$2.20-$0.02 (-0.9%)
Aerpio Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 4.35% below the high.
$9.81+$0.39 (+4.14%)
AlloVir, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.38% below the high.
